Brief: Oramed Completes Patient Enrollment In Pivotal Phase 3 Oral Insulin Study
03/05/2022 14:40
May 3 (Reuters) - Oramed Pharmaceuticals Inc ORMP.O :
* ORAMED COMPLETES PATIENT ENROLLMENT IN PIVOTAL PHASE 3 ORAL INSULIN STUDY
ORA-D-013-1
Source text for Eikon: ID:nPn8VtQrca
Further company coverage: ORMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results